Medtronic (NYSE:MDT), St. Jude Medical (NYSE:STJ), and Boston Scientific (NYSE:BSX) are three medical-device makers that pour hundreds of millions of dollars into research and development every year. What follows is a concrete example of how their technological devices save millions of lives.
At the recent mHealth Summit near Washington, D.C., the Fool's Max Macaluso and Rex Moore were able to speak with Robert McCray of the Wireless-Life Sciences Alliance. In this video, Rob explains how Medtronic, St. Jude, and Boston Scientific incorporate wireless technology in their defibrillators, and how it helps doctors and patients alike.
A full transcript follows the video.
The best stock for your portfolio in 2014
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
Robert McCray: One example is the big med-device companies: Medtronic (NYSE:MDT), St. Jude (NYSE:STJ), and Boston Scientific (NYSE:BSX). They all have competing defibrillators that are implanted, that collect information about the patient, and they save lives when there's a heart rhythm issue and they fire off.
Traditionally, a patient with a defibrillator -- an implant -- had to go into a doctor's office, who had a special device to pull information from that defibrillator and determine how the patient was doing, whether some adjustment to meds was required, whether the device itself had some defect.
Starting about eight years ago, all three of the companies put wireless systems in those defibrillators so that they could be read on a bedside monitor in the patient's home. As a result of that, based on one very large retrospective study, the life expectancy of patients with that connected health defibrillator was twice as good after five years as those that didn't have it. That's a concrete example.
They weren't paid for this, by the way. There's no extra reimbursement for this technology. It just made their product better.
Max Macaluso, Ph.D. has no position in any stocks mentioned. Rex Moore has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.